Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: NIHR Journals Library 2010-01-01
Reeks:Health Technology Assessment
Onderwerpen:
bevacizumab
sorafenib-tosylate
sunitinib
temsirolimus
renal-cell-carcinoma
systematic-review
economic-evaluation
Online toegang:https://doi.org/10.3310/hta14020
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items